ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes FRIDAY, June 12, 2026 -- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
A monthly treatment can cost up to $1,000
Each vegan capsule delivers 637.5mg of Acetyl L-Carnitine (ALCAR) from 750mg of Acetyl L-Carnitine HCl. ALCAR crosses the blood-brain barrier efficiently and provides an acetyl group for acetylcholine synthesis in the brain. At the recommended dose of 3 capsules per day, this formula delivers 1912.5mg of ALCAR daily
For oral semaglutide, the OASIS 4 trial behind the Wegovy pill reported a mean weight loss of about 16.6% at 64 weeks among participants who stayed on treatment (around 13.6% across all participants)
